A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML

Guillermo Garcia-Manero; James McCloskey; Elizabeth A. Griffiths; Karen W.L. Yee; Amer M. Zeidan; Aref Al-Kali; H. Joachim Deeg; Mitchell Sabloff; Mary Margaret Keating; Nancy Zhu; Nashat Y. Gabrail; Salman Fazal; Joseph Maly; Olatoyosi Odenike; Amy E. DeZern; Casey L. O’Connell; Gail J. Roboz; Lambert Busque; Rena Buckstein; Harshad Amin; Brian Leber; Aditi Shastri; Aram Oganesian; Harold N. Keer; Mohammad Azab; Michael R. Savona

Journal ArticleOPEN ACCESS

A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML

Future Oncology (2025) 21(8) 929-941

DOI: 10.1080/14796694.2025.2468578

0Citations

4Readers

Cite

CITATION STYLE

APA

Garcia-Manero, G., McCloskey, J., Griffiths, E. A., Yee, K. W. L., Zeidan, A. M., Al-Kali, A., … Savona, M. R. (2025). A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Future Oncology, 21(8), 929–941. https://doi.org/10.1080/14796694.2025.2468578

A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML

Cite

Register to see more suggestions